Absci IPO
Absci is a drug discovery company that uses artificial intelligence and synthetic biology to create better antibody drugs. The company's AI-driven approach to drug discovery and its partnerships with major pharmaceutical companies have positioned it as an innovative player in the biotech industry.
What We Know
Absci went public in July 2021 through a traditional IPO, raising approximately $200 million. The company trades on NASDAQ under the ticker symbol 'ABSI', with shares initially priced at $16 per share. Since going public, Absci has continued to advance its AI-powered drug discovery platform and expand partnerships with pharmaceutical companies. Like many biotech stocks, the share price has experienced volatility reflecting broader market conditions and investor sentiment toward early-stage biotechnology companies focused on platform technologies rather than late-stage drug candidates.
Frequently Asked Questions
Has Absci had an IPO?
Yes, Absci completed its IPO in July 2021, raising approximately $200 million. The AI-driven drug discovery company now trades on NASDAQ under the ticker symbol 'ABSI'.
When is the Absci IPO date?
Absci already went public in July 2021, so there is no upcoming IPO date. The company completed its initial public offering and began trading on NASDAQ.
How can I buy Absci stock?
You can purchase Absci stock through any major brokerage since it trades publicly on NASDAQ under ticker 'ABSI'. Shares are available for trading during regular market hours through standard investment accounts.
Don't Miss the Next Big IPO
Get notified when the next major company files for an IPO. Daily alerts delivered to your inbox.
Get IPO Alerts